DK155712C - Fremgangsmaade til fremstilling af et oligopeptid, som selektivt inhiberer formeringen af normale og leukaemiske myeloide celler - Google Patents
Fremgangsmaade til fremstilling af et oligopeptid, som selektivt inhiberer formeringen af normale og leukaemiske myeloide cellerInfo
- Publication number
- DK155712C DK155712C DK015281A DK15281A DK155712C DK 155712 C DK155712 C DK 155712C DK 015281 A DK015281 A DK 015281A DK 15281 A DK15281 A DK 15281A DK 155712 C DK155712 C DK 155712C
- Authority
- DK
- Denmark
- Prior art keywords
- radical
- separates
- value
- referred
- charge
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 210000000066 myeloid cell Anatomy 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 abstract 3
- 239000004472 Lysine Substances 0.000 abstract 3
- 102000015636 Oligopeptides Human genes 0.000 abstract 3
- 108010038807 Oligopeptides Proteins 0.000 abstract 3
- 210000003743 erythrocyte Anatomy 0.000 abstract 3
- 210000003714 granulocyte Anatomy 0.000 abstract 3
- 241000024188 Andala Species 0.000 abstract 2
- 101100505076 Caenorhabditis elegans gly-2 gene Proteins 0.000 abstract 2
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 abstract 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 2
- 229930182816 L-glutamine Natural products 0.000 abstract 2
- 239000004473 Threonine Substances 0.000 abstract 2
- 229960003767 alanine Drugs 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 239000000284 extract Substances 0.000 abstract 2
- 238000005194 fractionation Methods 0.000 abstract 2
- 238000005227 gel permeation chromatography Methods 0.000 abstract 2
- 229960002989 glutamic acid Drugs 0.000 abstract 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000006194 liquid suspension Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 230000001376 precipitating effect Effects 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 229960001153 serine Drugs 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 229960003080 taurine Drugs 0.000 abstract 2
- 229960002898 threonine Drugs 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001557 animal structure Anatomy 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 244000309466 calf Species 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 238000001962 electrophoresis Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/838—Marrow; spleen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU6880 | 1980-01-15 | ||
| HU8068A HU182087B (en) | 1980-01-15 | 1980-01-15 | Process for preparing an active substance for the selective inhibition of the multiplication of normal cells and of cells in myeloide leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK15281A DK15281A (da) | 1981-07-16 |
| DK155712B DK155712B (da) | 1989-05-08 |
| DK155712C true DK155712C (da) | 1989-09-25 |
Family
ID=10947737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK015281A DK155712C (da) | 1980-01-15 | 1981-01-14 | Fremgangsmaade til fremstilling af et oligopeptid, som selektivt inhiberer formeringen af normale og leukaemiske myeloide celler |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4384991A (da) |
| EP (1) | EP0035102B1 (da) |
| JP (1) | JPS56138118A (da) |
| AT (1) | ATE5071T1 (da) |
| AU (1) | AU542044B2 (da) |
| DE (1) | DE3161195D1 (da) |
| DK (1) | DK155712C (da) |
| HU (1) | HU182087B (da) |
| SU (2) | SU1367837A3 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0085254A1 (en) * | 1981-12-28 | 1983-08-10 | Yoshio Sakagami | Proteins and their extraction |
| US4572834A (en) * | 1984-04-10 | 1986-02-25 | Clinical Reference Laboratory, Inc. | Biologic and method of preparing same |
| US5149544A (en) * | 1989-11-13 | 1992-09-22 | Research Corporation Technologies, Inc. | Method of inhibiting progenitor cell proliferation |
| UA27048C2 (uk) * | 1993-10-18 | 2000-02-28 | Центр Ембріональних Тканин "Емселл" | Лікарський препарат імуhокоригуючої дії hа осhові клітиhhої суспеhзії, спосіб лікуваhhя цукрового діабету з використаhhям цього препарату |
| EP1640012A1 (de) * | 2004-09-24 | 2006-03-29 | Salama, Zoser B. nat.rer.Dr. | Pharmazeutisches Mittel enthaltend Blutbestandteile 10 kDa und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems |
| US20060067942A1 (en) * | 2004-09-24 | 2006-03-30 | Salama Zoser B | Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
| CA2580192A1 (en) * | 2004-09-24 | 2006-03-30 | Zoser B. Salama | Pharmaceutical product containing blood constituents and or kda, and the use of the same for the prophylaxis and treatment of defects of the immune system |
| DE102004047262A1 (de) * | 2004-09-24 | 2006-04-06 | Ipss International Pharmaceutical Strategies & Solutions | Pharmazeutisches Mittel umfassend Blutprodukte und deren Verwendung als Injektions- oder Infusionsmittel zur Prophylaxe und Behandlung von Defekten des Immunsystems beim Menschen |
| US7834184B2 (en) | 2004-11-04 | 2010-11-16 | Mallinckrodt Inc. | Opiate intermediates and methods of synthesis |
| US7511060B2 (en) | 2005-10-21 | 2009-03-31 | Mallinckrodt Inc. | Opiate intermediates and methods of synthesis |
| US7622586B2 (en) * | 2005-10-21 | 2009-11-24 | Mallinckrodt Inc. | Opiate intermediates and methods of synthesis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3973001A (en) * | 1954-04-27 | 1976-08-03 | Solco Basel Ag | Tissue cell stimulating blood extracts |
| US3937816A (en) * | 1970-07-21 | 1976-02-10 | Solco Basel Ag | Growth regulating compositions extracted from spleen |
| GB1579120A (en) * | 1975-08-05 | 1980-11-12 | Union International Co Ltd | Extracts of the haemopoietic system |
-
1980
- 1980-01-15 HU HU8068A patent/HU182087B/hu not_active IP Right Cessation
-
1981
- 1981-01-08 US US06/223,366 patent/US4384991A/en not_active Expired - Fee Related
- 1981-01-13 JP JP275381A patent/JPS56138118A/ja active Pending
- 1981-01-14 AU AU66200/81A patent/AU542044B2/en not_active Ceased
- 1981-01-14 DK DK015281A patent/DK155712C/da not_active IP Right Cessation
- 1981-01-14 SU SU813230703A patent/SU1367837A3/ru active
- 1981-01-15 EP EP81100268A patent/EP0035102B1/de not_active Expired
- 1981-01-15 AT AT81100268T patent/ATE5071T1/de not_active IP Right Cessation
- 1981-01-15 DE DE8181100268T patent/DE3161195D1/de not_active Expired
-
1982
- 1982-02-23 SU SU823396892A patent/SU1228776A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| DK155712B (da) | 1989-05-08 |
| AU542044B2 (en) | 1985-02-07 |
| EP0035102A1 (de) | 1981-09-09 |
| US4384991A (en) | 1983-05-24 |
| SU1228776A3 (ru) | 1986-04-30 |
| SU1367837A3 (ru) | 1988-01-15 |
| DK15281A (da) | 1981-07-16 |
| ATE5071T1 (de) | 1983-11-15 |
| HU182087B (en) | 1983-12-28 |
| DE3161195D1 (en) | 1983-11-24 |
| EP0035102B1 (de) | 1983-10-19 |
| AU6620081A (en) | 1982-04-22 |
| JPS56138118A (en) | 1981-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The 68,000-dalton neurofilament-associated polypeptide is a component of nonneuronal cells and of skeletal myofibrils | |
| Press et al. | The N-and c-terminal amino acid sequences of the heavy chain from a pathological human immunoglobulin IgG | |
| DK155712C (da) | Fremgangsmaade til fremstilling af et oligopeptid, som selektivt inhiberer formeringen af normale og leukaemiske myeloide celler | |
| Brand et al. | Chemical, clinical, and immunological studies on the products of human plasma fractionation. III. Amino acid composition of plasma proteins | |
| Dulak et al. | A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication‐stimulating activity for embryo fibroblasts | |
| Ketterer et al. | The isolation of carcinogen-binding protein from livers of rats given 4-dimethylaminoazobenzene | |
| Yip et al. | Photoaffinity labeling of atrial natriuretic factor receptors of rat kidney cortex plasma membranes. | |
| Brew et al. | The characterization of the whey proteins of guinea-pig milk: The isolation and properties of α-lactalbumin | |
| Kolk et al. | Isolation, chemical and immunological characterization of two strongly basic nuclear proteins from human spermatozoa | |
| McMeekin | Serum albumin. I. The preparation and properties of crystalline horse serum albumin of constant solubility | |
| Chiari et al. | Preincubation with cysteine prevents modification of sulfhydryl groups in proteins by unreacted acrylamide in a gel | |
| Furth et al. | Studies on the subunit structure and amino acid sequence of triose phosphate isomerase from chicken breast muscle | |
| Alais et al. | Isolation, purification, and analysis of two κ-casein-like fractions from sheep casein | |
| Donato et al. | Cardiac S-100a0 protein: purification by a simple procedure and related immunocytochemical and immunochemical studies | |
| Mäkelä et al. | Release of sialic acid and carbohydrates from human red cells by trypsin treatment | |
| Regoeczi et al. | Effects of clotting on the label in iodinated fibrinogen in different species | |
| Stratton et al. | The role of zeta potential in Rh agglutination | |
| Strawich et al. | Synthesis and degradation in vivo of a phosphoprotein from rat dental enamel. Identification of a phosphorylated precursor protein in the extracellular organic matrix | |
| US4376071A (en) | Mitogenic spinal cord growth factor | |
| US4798800A (en) | Process for isolating human globular domain NC1 of basal membrane collagen from human tissue | |
| Kownatzki | Studies on a fragment of human IgM macroglobulins related to “J chain” | |
| Pinder et al. | Spectrin in primitive erythrocytes | |
| Sulochana et al. | Purification and characterization of a novel 88 kDa protein from serum and vitreous of patients with Eales’ disease | |
| SU940066A1 (ru) | Способ разделени эритроцитов на строму и гемоглобин | |
| Webster et al. | A second activation peptide from bovine cationic trypsinogen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |